Assessment of Glutamatergic Neurosystem in FXS

MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy

MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.

The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.

Three visits at Massachusetts General Hospital are required:

Medical history and behavioral testing (approx. 1.5 hours)
PET-MRI (approx. 2 hours)
Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
(617) 726-6913

Our Most Recent Opportunities

If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

Survey: Share Your Experience With Telehealth and Services During COVID

Parents or caregivers of individuals with Fragile X syndrome who has received services via telehealth during the COVID-19 pandemic may be eligible to participate.

Study: Focus Group on Difficulty with Changes and Rigid/Inflexible Behaviors in Fragile X Syndrome

Individuals with FXS who are 18 years or older and able to talk fluently about own experiences, and their caregivers and providers may be eligible to participate. Eligible providers include teachers, psychologists, social workers, and physicians.

Study: Adult Fragile X Premutation Carriers Needed for Registry

NFXF has partnered with an advisory committee of international fragile X professionals to create an international fragile X premutation research registry. Find out how to participate.

Survey: Cannabidiol (CBD) Use with Fragile X Syndrome

A Mount Sinai Genetic Counseling graduate student is conducting a research study to learn about possible benefits and side effects of CBD supplements when used to treat FXS symptoms. This information will be obtained by using an anonymous online parental and caregiver survey. About the Survey Who can participate? Parents and caregivers caring for somebody with FXS who uses, or has used, CBD supplements may be eligible to participate. The parent or caregiver responding to the survey must be at least 18 years old. The individual with ...

Exploring the Most Important Information for New Premutation Carriers

Participants of this study will explore what information is considered most important to recently diagnosed fragile X premutation carriers. Open to premutation carriers 18 and over who were diagnosed sometime since January 2018.

Parents and Caregivers of Adults with Fragile X Syndrome Needed for a Survey

Kaylynn Shuleski, a master’s in genetic counseling candidate, is conducting a research study to explore the concerns and challenges caregivers may face when planning long-term supports and living arrangements for their adult children with Fragile X syndrome (FXS). This information will be valuable for current and future families when considering long-term supports, as well as for healthcare professionals, counselors, and policy makers. About the Study Who can participate? Parents and caregivers of adults with full mutation ...